刘艾林，女，博士，研究员，博士生导师，PI。1995年至今在中国医学科学院药物研究所工作。1998年-2000年参与筹建了国家药物筛选中心。2004年至今一直参与国家人口与健康科学数据共享平台建设工作。2018年-2019年在美国Purdue University访问学习。主要从事防治神经退行性疾病新药、抗感染新药的发现与机制研究，以及计算药理学，网络药理学和药物信息学研究。
兼任世界中医药学会联合会网络药理学专业委员会常务理事，中国民族医药学会药理与毒理学分会理事，中国药理学会网络药理学专业委员会常务理事，北京精神神经药理专业委员会委员，国内外若干核心期刊审稿专家，项目评审专家等社会职务。

1、防治神经退行性疾病新药发现与机制研究
2、抗感染新药发现与机制研究
3、计算药理学，网络药理学，药物信息学

1、Ailin Liu*#, Jun Zhao#, Nicholas J. Huls, Matthias Zeller, Lin Wang, Tonglei Li*. The Structural Basis of DL0410, A Novel Multi-Target Candidate Drug for the Treatment of Alzheimer’s Disease. Crystals 2024, 14(1), 59. https://doi.org/10.3390/cryst14010059.
2、Xu L#, Cai C#, Fang J, Wu Q, Zhao J, Wang Z, Guo P, Zheng L*, Liu A*. Systems pharmacology dissection of pharmacological mechanisms of Xiaochaihu decoction against human coronavirus. BMC Complement Med Ther. 2023 Jul 20;23(1):252. doi: 10.1186/s12906-023-04024-6.
3、Zhao J, Xu L, Bai Y, Wang C, Guo P, Wang Z, Du G, Liu A*. The efficacy and mechanism of salmeterol against influenza A virus in vitro and in vivo. Int Immunopharmacol. 2023 Jun;119:110226. doi: 10.1016/j.intimp.2023.110226.
4、Jun Zhao, Qinhai Ma, Baoyue Zhang, Pengfei Guo, Zhe Wang, Yi Liu, Minsi Meng, Ailin Liu*, Zifeng Yang*, and Guanhua Du*. Exploration of SARS-CoV‑2 3CLpro Inhibitors by Virtual Screening Methods, FRET Detection, and CPE Assay. Journal of Chemical Information and Modeling, 2021 Dec 27;61(12):5763-5773. https://doi.org/10.1021/acs.jcim.1c01089
5、Cai C, Xu L, Fang J, Dai Z, Wu Q, Liu X, Wang Q, Fang J*, Liu AL*, Du GH*. In Silico Prediction and Bioactivity Evaluation of Chemical Ingredients Against Influenza A Virus From Isatis tinctoria L. Front Pharmacol. 2021 Dec 7;12:755396. doi: 10.3389/fphar.2021.755396.
6、Mengwu Xiao#, Lvjie Xu#, Ding Lin, Wenwen Lian, Manying Cui, Meng Zhang, Xiaowei Yan, Shuishi Li, Jun Zhao, Jiao Ye, Ailin Liu*, Aixi Hu*. Design, synthesis, and bioassay of 4-thiazolinone derivatives as influenza neuraminidase inhibitors[J]. European Journal of Medicinal Chemistry. 2021 Mar 5;213:113161.
7. Xu L#, Jiang W#, Jia H, Zheng L, Xing J, Liu A*, Du G*. Discovery of Multitarget-Directed Ligands Against Influenza A Virus From Compound Yizhihao Through a Predictive System for Compound-Protein Interactions. Front Cell Infect Microbiol. 2020 Feb 11;10:16. doi: 10.3389/fcimb.2020.00016.
8、Chen A, Liang Y, Ye J, Hu A*, Lian W, Liu A*, Du G. Synthesis of Chalcone Derivatives Containing Furan or/and Pyran Ring as Neuraminidase Inhibitors. Chem Res Chinese Universities, 2019, 35(3):395-402.
9、Li C, Xu LJ, Lian WW, Pang XC, Jia H, Liu AL*, Du GH*. Anti-influenza effect and action mechanisms of the chemical constituent gallocatechin-7-gallate from Pithecellobium clypearia Benth. Acta Pharmacol Sin. 2018, 39(12):1913-1922.
10、Liu J*#, Zu M#, Chen K, Gao L, Min H, Zhuo W, Chen W, Liu A*. Screening of neuraminidase inhibitory activities of some medicinal plants traditionally used in Lingnan Chinese medicines. BMC Complement Altern Med. 2018, 18(1):102. doi: 10.1186/s12906-018-2173-1.
11、Liu J*, Zu M, Chen K, Gao L, Min H, Zhou W, Chen W, and Liu A*. Screening of neuraminidase inhibitory activities of some medicinal plants traditionally used in Lingnan Chinese medicines. BMC Complementary and Alternative Medicine, 2018, 18:102. https://doi.org/10.1186/ s12906-018-2173-1.
12、Li C, Song X, Song J, Pang X, Wang Z, Zhang Y, Lian W, Liu A*, Du G*. Pharmacokinetic study of gallocatechin-7-gallate from Pithecellobiumclypearia Benth. in rats. Acta Pharmaceutica Sinica B, 2016, 6(1): 64-70.
13、 Zu M#, Li C#, Fang JS, Lian WW, Liu AL*, Zheng LS*, Du GH*. Drug discovery of host CLK1 inhibitors for influenza treatment. Molecules, 2015, 20, 19735–19747.
14、Zhang B, Zhao J, Wang Z, Guo P, Liu A* and Du G*. Identification of Multi-Target Anti-ADChemical Constituents From Traditional Chinese Medicine Formulae by Integrating Virtual Screening and In Vitro Validation. Front. Pharmacol., 2021, 12:709607. doi: 10.3389/fphar.2021.709607.
15、 Zhou W, Lian WW, Yan R, Jia H, Xu LJ, Wang L, Liu AL*, Du GH*. DL0410 ameliorates cognitive deficits in APP/PS1 transgenic mice by promoting synaptic transmission and reducing neuronal loss. Acta Pharmacol Sin. 2020, 41(5):599-611.
16、Lian WW, Zhou W, Zhang BY, Jia H, Xu LJ, Liu AL*, Du GH*. DL0410 ameliorates cognitive disorder in SAMP8 mice by promoting mitochondrial dynamics and the NMDAR-CREB-BDNF pathway. Acta Pharmacol Sin. 2020 Aug 31. doi:10.1038/s41401-020-00506-2.
17、Zhang B, Zhao J, Wang Z, Xu L, Liu A*, Du G*. DL0410 attenuates oxidative stress and neuroinflammation via BDNF/TrkB/ERK/CREB and Nrf2/HO-1 activation. Int Immunopharmacol. 2020 Jul 6;86:106729. doi: 10.1016/j.intimp.2020.106729.
18、 Pang X#, Zhang B#, Mu G, Xia J, Xiang Q, Zhao X, Liu A*, Du G*, Cui Y*. Screening of cytochrome P450 3A4 inhibitors via in silico and in vitro approaches. RSC Adv, 2018, 8, 34783-34792.
19、 Pang X, Zhao Y, Song J, Kang, Wu S, Wang L, Liu A*, Du G*. Pharmacokinetics, excretion and metabolites analysis of DL0410, a dual acting cholinesterase inhibitor and histamine 3 receptor antagonist. Mol Med Rep. 2019, 20: 1103-1112.
20、Pang X, Fu W, Wang J, Kang D, Xu L, Zhao Y, Liu AL*, Du GH*. Identification of estrogen receptor α antagonists from natural products By virtual screening approaches. Oxid Med Cell Longev. 2018, 2018: 6040149. doi:10.1155/2018/6040149.
21、Pang XC, Kang D, Fang JS, Zhao Y, Xu VJ, Lian WW, Liu AL*, Du GH*. Network pharmacology-based analysis of Chinese herbal Naodesheng formula for application to Alzheimer’s Disease. Chinese Journal of Natural Medicines, 2018, 16(1): 0053-0062.
22、 Lian W, Fang J, Xu L, Zhou W, Kang D, Xiong W, Jia H, Liu AL*, Du GH*. DL0410 Ameliorates Memory and Cognitive Impairments Induced by Scopolamine via Increasing Cholinergic Neurotransmission in Mice. Molecules. 2017, 22(3), 410. pii: E410.
23、Lian W, Jia H, Xu L, Zhou W, Kang D, Liu A*, Du G*. Multi-Protection of DL0410 in Ameliorating Cognitive Defects in D-Galactose Induced Aging Mice. Front Aging Neurosci. 2017, 9:409. doi: 10.3389/fnagi.2017.00409.
24、 Fang J, Wang L, Li Y, Lian W, Pang X, Wang H, Yuan D, Wang Q*, Liu AL*, Du GH*. AlzhCPI: A knowledge base for predicting chemical-protein interactions towards Alzheimer's disease. PLoS One. 2017 May 25;12(5):e0178347. doi: 10.1371/journal.pone.0178347. eCollection 2017.
25、Pang X, Zhao Y, Wang J, Li W, Xiang Q, Zhang Z, Wu S, Liu AL*, Cui YM* and Du GH*. Competing endogenous RNA and co-expression network analysis for identification of potential biomarkers and therapeutics in association with metastasis risk and progression of prostate cancer. Oxid Med Cell Longev. 2019, 2019:8265958.
26、Zhang BY, Zheng YF, Pang XC, Wang Z, Ding H, Liu AL*. Network Pharmacology based Study of the Active Constituents of Chinese Medicinal Formulae for Antitumor Mechanism. World J Tradit Chin Med, 2018, 4(2):43-53.
27、 Kang D, Pang X, Lian W, Xu L, Wang,J, Jia H, Zhang B, Liu AL*, Du GH*. Discovery of VEGFR2 inhibitors by integrating naıve Bayesian classification, molecular docking and drug screening approaches. RSC Advances, 2018, 8: 5286- 5297.

1、《实验药理学》（第二版）。编者，北京：高等教育出版社，2020年。
2、《迈向药物创新之路—“1035工程”实施回顾》。编者，北京：高等教育出版社，2019年。
3、《中药材“毒”古今研究概评》。编委，北京：中国医药科技出出版社，2019年。
4、《天然小分子药物》。编委，北京：人民卫生出版社，2018年。
5、 Natural Small Molecule Drugs from Plants. Springer, 2018.
6、 Dietary Phytochemicals and Microbes. Compiled Chapter 3 (pp33-126). Springer sciences, Business Media Dordrecht, 2012.

1. 刘艾林，谭文杰，郑丽舒，许律捷，赵君，吴松，康洁，张文轩，叶飞，郭鹏飞，李超，贾皓，杜冠华。没食子儿茶素-7-没食子酸酯在抗冠状病毒药物中的用途。申请日期：2021年3月15日，申请号：202110276445.2。
2. 刘艾林，吴松，杜冠华，王冬梅，方坚松，周围，连雯雯，庞晓丛。金雀异黄酮衍生物在多靶点改善学习记忆障碍中的作途，申请日期：2016年12月26日，申请号：2016112071083
3. 杜冠华，吴松，刘艾林，周丹，王冬梅，冯章英，李莉，刘前，一个异黄酮衍生物的多靶点作用及其改善学习记忆用途，专利号：ZL201310113150.9，授权日期：2019年1月1日。
4. 秦海林，方莲花，张志辉，刘艾林，邓安珺，袁天翊，于金倩，李志宏，杜冠华。黄连碱衍生物、其合成方法及其抗肿瘤的药物用途，专利号：ZL201210411739.2，授权公告日：2016年09月14日。
5. 刘艾林，杜冠华，王琳，高梅，宫丽丽。对乙、丁酰胆碱酯酶具有双重抑制活性的化合物及其用途。专利号：ZL 200710107604.6。

1. 2011 年，“天然产物的生物活性评价研究”获得中华医学科技奖，叁等奖，
主要完成人：杜冠华， 刘艾林，张天泰，王月华，张莉，方莲花，陈若云，秦海林。
2. 2009 年，“新型高通量药物筛选用蛋白质芯片技术的研究与应用” 获北京市科学技术奖，贰等奖。主要完成人：杜冠华，周勇，张天泰，高峰， 刘艾林，方莲花，张莉，胡娟娟，王月华，何国荣。
3. 2002年，“高通量药物筛选技术体系的研究与应用” 获北京市科学技术奖,贰等奖，主要完成人：杜冠华，王晓良，胡娟娟， 刘艾林，黄家学，尚念勇，孙缅恩，张莉，肖玉霞。
4. 2002 年，“高通量药物筛选技术体系的研究与应用”获中华医学科技奖，叁等奖。主要完成人：杜冠华，王晓良，胡娟娟， 刘艾林，黄家学，尚念勇，孙缅恩，张莉。
5. 2018 年，“天然产物成药性评价技术创新及应用”于 获得中华医学科技奖，叁等奖。主要完成人：杜冠华，王月华，方莲花，吕扬，张莉，杨秀颖， 刘艾林，王守宝。